MDT - Medtronic plc

NYSE - NYSE Delayed Price. Currency in USD
112.06
+2.85 (+2.61%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close109.21
Open109.94
Bid111.52 x 1300
Ask112.45 x 800
Day's Range109.90 - 112.15
52 Week Range81.66 - 112.15
Volume6,223,634
Avg. Volume4,160,817
Market Cap150.348B
Beta (3Y Monthly)0.62
PE Ratio (TTM)34.36
EPS (TTM)3.26
Earnings DateNov 19, 2019
Forward Dividend & Yield2.16 (1.98%)
Ex-Dividend Date2019-09-26
1y Target Est118.48
  • Benzinga

    Barron's Picks And Pans: Medtronic, Tesla, Walmart And More

    This weekend's Barron's cover story explains how to generate income in retirement. Other featured articles discuss big tech's take on banking and retailers that have been left behind. Also, the prospects ...

  • Reuters

    UPDATE 1-Stents no better than drugs for many heart patients -U.S. study

    Many patients with severe but stable heart disease who routinely undergo invasive procedures to clear and prop open clogged arteries would do as well by just taking medications and making lifestyle changes, U.S. researchers reported on Saturday. The $100 million government-backed study, presented at the American Heart Association (AHA) meeting in Philadelphia, is the largest yet to look at whether procedures to restore normal blood flow in patients with stable heart disease offers an added benefit over more conservative treatment with aspirin, cholesterol-lowering drugs and other measures. At least two prior studies determined that artery-clearing and stenting or bypass surgery in addition to medical treatment does not significantly lower the risk of heart attacks or death compared with non-invasive medical approaches alone.

  • Barrons.com

    Medtronic Stock Could Rise Even More on Plans to Sell a Lot More Pacemakers

    Potential market for its tiny Micra cardiac device could more than triple if regulators approve new use.

  • Earnings Reports for the Week of Nov. 18-22 (HD, M, TGT)
    Kiplinger

    Earnings Reports for the Week of Nov. 18-22 (HD, M, TGT)

    Check out our weekly earnings calendar and read the latest quarterly earnings previews.

  • GlobeNewswire

    Medtronic Highlights Leadership in Inclusion, Diversity, and Equity in 2019 Integrated Performance Report

    The Medtronic 2019 Integrated Performance Report Shares Progress on Pay Equity, Diversity in Management Roles, Access to Healthcare, Environmental Performance, UN Sustainable.

  • Here's Why You Should Add NuVasive (NUVA) to Your Portfolio
    Zacks

    Here's Why You Should Add NuVasive (NUVA) to Your Portfolio

    Investors continue to be optimistic about NuVasive's (NUVA) stellar performance.

  • Medtronic (MDT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks

    Medtronic (MDT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Medtronic (MDT) Releases Positive Study Results on Pacemaker
    Zacks

    Medtronic (MDT) Releases Positive Study Results on Pacemaker

    Medtronic (MDT) presents favorable results from study on leadless pacemaker, indicating potential for improving cardiac functions in patients having blockages.

  • Medtronic (MDT) Gains As Market Dips: What You Should Know
    Zacks

    Medtronic (MDT) Gains As Market Dips: What You Should Know

    Medtronic (MDT) closed at $107.97 in the latest trading session, marking a +0.88% move from the prior day.

  • GlobeNewswire

    New Study Shows Promise in Treating More Patients with World’s Smallest Pacemaker

    DUBLIN, Nov. 11, 2019 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) today announced results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study showing that an investigational set of algorithms in the Micra™ Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with impaired electrical conduction between the chambers of the heart, called atrioventricular (AV) block. The results from the MARVEL 2 study will be presented Nov. 16 during a Featured Science session at American Heart Association 2019, the AHA Scientific Sessions and were published today in JACC: Clinical Electrophysiology.

  • Is Medtronic plc (NYSE:MDT) An Attractive Dividend Stock?
    Simply Wall St.

    Is Medtronic plc (NYSE:MDT) An Attractive Dividend Stock?

    Dividend paying stocks like Medtronic plc (NYSE:MDT) tend to be popular with investors, and for good reason - some...

  • American City Business Journals

    Memphis biotech conference unites investors, startups, major players

    “We have 22 presenting companies on the agenda, and they are the stars of the show. It is the place for startups and the entrepreneurs who run them, the investors that support them … and the strategic partners that hopefully buy them.”

  • Minnesota business execs place the most — and biggest — bets on Klobuchar for president
    American City Business Journals

    Minnesota business execs place the most — and biggest — bets on Klobuchar for president

    Minnesota’s business leaders were by a large margin backing U.S. Sen. Amy Klobuchar (D-Minn.) in the early stages of 2020 presidential election.

  • Global Investment Presents Opportunity
    Investopedia

    Global Investment Presents Opportunity

    While U.S. markets pause, there could be opportunities in international investments, and health care stocks are becoming more attractive.

  • Medtronic (MDT) Dips More Than Broader Markets: What You Should Know
    Zacks

    Medtronic (MDT) Dips More Than Broader Markets: What You Should Know

    Medtronic (MDT) closed at $105.53 in the latest trading session, marking a -1.51% move from the prior day.

  • GlobeNewswire

    Four-Year Data from the IN.PACT Global Study Highlight Durable Performance and Safety of IN.PACT™ Admiral™ DCB

    DUBLIN and LAS VEGAS, Nov. 05, 2019 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) today announced four-year data from the IN.PACT Global study, which reinforce the long-term durability and safety of the IN.PACT™ Admiral™ drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries. Professor Thomas Zeller, M.D., director of the Department of Angiology at Universitaets-Herzzentrum, Freiburg-Bad Krozingen, Germany, presented the new, four-year results from the full clinical cohort of the IN.PACT Global Study. The results are the first four-year, real-world, fully adjudicated DCB data to be presented in a scientific congress.

  • GlobeNewswire

    Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2020

    Medtronic plc (MDT) announced today that it will report financial results for the second quarter of fiscal year 2020 on Tuesday, November 19, 2019. The news release will include summary financial information for the company’s second quarter of fiscal year 2020, which ended on Friday, October 25, 2019. Medtronic will host a webcast at 7:00 a.m. CST to discuss financial results for its second quarter of fiscal year 2020.

  • Analysts Bullish on Axonics' Prospects
    GuruFocus.com

    Analysts Bullish on Axonics' Prospects

    Rated a buy with target set 40% above current stock price Continue reading...

  • American Century Equity Income Focuses on Value
    Kiplinger

    American Century Equity Income Focuses on Value

    This fund chooses high-quality but overlooked stocks.

  • United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up
    Zacks

    United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up

    United Therapeutics (UTHR) beats estimates on both fronts in the third quarter. Stock rises in response

  • Medtronic Introduces Robotics Challenger to Intuitive System
    GuruFocus.com

    Medtronic Introduces Robotics Challenger to Intuitive System

    A move aimed at strengthening the medical device firm’s position in the surgical market Continue reading...

  • GlobeNewswire

    Medtronic Announces Shonin Approval and Launch of the Valiant Navion™ Thoracic Stent Graft System in Japan

    Medtronic plc (MDT) today announced Shonin approval from the Ministry of Health, Labour and Welfare (MHLW) and the launch of the Valiant Navion™ thoracic stent graft system in Japan for the minimally invasive repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD). The news marks the third major geographical launch of the Valiant Navion, following FDA and CE Mark approvals in late 2018. The low-profile Valiant Navion system is built to further improve upon the performance of the market-leading Valiant™ Captivia™ thoracic stent graft system, which has treated more than 100,000 patients globally, while also broadening patient applicability.

  • Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know

    Medtronic (MDT) closed at $108.55 in the latest trading session, marking a +0.93% move from the prior day.

  • GlobeNewswire

    Medtronic Launches New Activa™ Patient Programmer for DBS Therapy

    Medtronic plc (MDT) today announced the U.S. launch of its advanced Patient Programmer technology for Deep Brain Stimulation (DBS) therapy at the Samsung Developers Conference in San Jose, Calif. The new programmer – which received U.S. Food and Drug Administration (FDA) approval on July 3, 2019 – leverages a user-friendly, custom-configured Samsung mobile device which allows patients to manage their therapy more simply and discreetly. To date, more than 150,000 patients have been implanted with Medtronic DBS devices for management of Parkinson’s symptoms and other conditions. “It is important for patients to have access to advanced technology for user-friendly therapy management at home,” says Sandeep Thakkar, D.O., neurologist and movement disorder specialist at Hoag’s Pickup Family Neurosciences Institute.

  • This Hedge Fund Can Still Deliver Double Digit Returns: Here Are Its Top Picks
    Insider Monkey

    This Hedge Fund Can Still Deliver Double Digit Returns: Here Are Its Top Picks

    Tamarack Capital Management was founded by Justin John Ferayorni, who remained the fund’s Chief Investment Officer and Portfolio Manager. Mr. Ferayorni holds A.B. degree in Chemistry from Princeton University, as well as Chartered Financial Analyst designation. Prior to founding Tamarack Capital Management, he worked as Healthcare Analyst and Portfolio Manager. He also held a position of […]